Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.
NSCLC TUMOR BOARD: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings
Release Date: December 23, 2021
Expiration Date: December 23, 2022
Activity Overview
Lung cancer is the second most common cancer in both men and women and most patients with lung cancer are diagnosed with advanced disease and face poor survival outcomes. The development of immune checkpoint inhibitors has led to a paradigm shift in the treatment of multiple tumor types, including lung cancer in recent years. Single-agent immunotherapy has demonstrated superiority to standard chemotherapy in both pretreated and first-line settings in patients with metastatic non-small cell lung cancer (NSCLC) and is associated with a favorable safety profile. Optimal incorporation of immunotherapy into treatment paradigms for patients with NSCLC includes defining biomarkers, investigating immunotherapy-based combinations, and the use of immunotherapy as induction therapy.
This online, on-demand virtual symposium brings together renowned experts in thoracic oncology in a PER Tumor Board® educational format and focuses on imparting the latest data on immune checkpoint inhibition strategies and clinical trial achievements into real-world practice changes that will optimize outcomes among patients with lung cancer.
This educational activity is an archive of the live ancillary satellite educational symposium to the 2021 Multidisciplinary Thoracic Cancers Symposium held on December 1, 2021 in Scottsdale, Arizona.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the rationale for the application of immune checkpoint inhibitors into treatment plans for patients with early-stage and locally advanced, unresectable NSCLC;
- Assess efficacy and safety profiles of immune checkpoint blockade evaluated in patients with unresectable stage III NSCLC and resectable stage I to III NSCLC;
- Develop proactive strategies to identify and mitigate toxicities associated with immunotherapy-based regimens among patients with stage I to III NSCLC; and
- Translate evidence-based guidelines and updated data on immune checkpoint inhibitors in stage I to III NSCLC into personalized treatment plans, with a focus on improving collaboration and role harmonization between thoracic surgeons, radiation oncologists and medical oncologists.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Chair
Professor of Medicine (Oncology)
Division Chief, Oncology
Interim Medical Director, Stanford Cancer Center
Deputy Director, Stanford Cancer Institute
Stanford University Medical Center
Stanford, CA
Disclosures: Grant/Research Support: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Helsinn, Merck, Novartis, Pharmacyclics, Seagen, Xcovery; Consultant: AstraZeneca, Blueprint Medicines, Mirati.
Faculty
Associate Professor, Radiation Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures: Grant/Research Support: EMD Serono, Genentech, Merck; Consultant: Boston Scientific, Triptych Health Partners.
Associate Professor of Medicine
Division of Hematology & Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Merck, Novartis, Revolution Medicines, Spectrum; Consultant: Blueprint Medicines, Boehringer Ingelheim, Novartis, Teladoc; Other: Advisory Board: BeiGene, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Turning Point.
Albert Einstein College of Medicine
Montefiore Health System
Bronx, NY
Disclosures: Grant/Research Support: Bristol Myers Squib; Consultant: AstraZeneca, Pfizer, Genentech, Bristol Myers Squibb, Flame Biosciences, Galvanize Therapeutics; Shareholder: Pfizer (wife), PPD (wife), Xalud (wife); Other: Vice-Chair, Lung Cancer Research Foundation
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
